253 related articles for article (PubMed ID: 37010239)
1. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Garly R; Berg T; Jensen MB; Knoop A; Volmer L; Glavicic V; Khan H; Poulsen PB; Olsen J; Kümler I
Acta Oncol; 2023 Mar; 62(3):290-297. PubMed ID: 37010239
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
5. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
[TBL] [Abstract][Full Text] [Related]
8. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Cancer Treat Res Commun; 2022; 32():100573. PubMed ID: 35567914
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell J; Martínez MT; Ramos M; O'Connor M; de la Cruz-Merino L; Santaballa A; Martínez-Jañez N; Moreno F; Fernández I; Alarcón J; Virizuela JA; de la Haba-Rodríguez J; Sánchez-Rovira P; González-Cortijo L; Margelí M; Sánchez-Muñoz A; Antón A; Casas M; Bezares S; Rojo F
Eur J Cancer; 2022 Jan; 161():26-37. PubMed ID: 34902765
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Future Oncol; 2022 Jan; 18(3):349-362. PubMed ID: 34842454
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Watanabe K; Niikura N; Kikawa Y; Oba M; Kobayashi K; Tada H; Ozaki S; Toh U; Yamamoto Y; Tsuneizumi M; Okuno T; Iwakuma N; Takeshita T; Iwamoto T; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2023 Jun; 199(2):253-263. PubMed ID: 37000345
[TBL] [Abstract][Full Text] [Related]
15. Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population.
Zhang Y; Chen W; Chen S; Yang Q; Ouyang Z
Technol Cancer Res Treat; 2022; 21():15330338221132926. PubMed ID: 36310472
[No Abstract] [Full Text] [Related]
16. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
18. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
Porte B; Carton M; Lerebours F; Brain E; Loirat D; Haroun L; Bellesoeur A; Bach Hamba S; Kirova Y; Cottu P
Breast; 2020 Dec; 54():303-310. PubMed ID: 33242757
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H
Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115
[TBL] [Abstract][Full Text] [Related]
20. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
Trials; 2023 May; 24(1):338. PubMed ID: 37198674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
